keyword
MENU ▼
Read by QxMD icon Read
search

Free psa

keyword
https://www.readbyqxmd.com/read/29439820/germline-dna-repair-gene-mutations-and-outcomes-in-men-with-metastatic-castration-resistant-prostate-cancer-receiving-first-line-abiraterone-and-enzalutamide
#1
Emmanuel S Antonarakis, Changxue Lu, Brandon Luber, Chao Liang, Hao Wang, Yan Chen, John L Silberstein, Danilo Piana, Zhao Lai, Yidong Chen, William B Isaacs, Jun Luo
BACKGROUND: Inherited DNA-repair gene mutations are more prevalent in men with advanced prostate cancer than previously thought, but their clinical implications are not fully understood. OBJECTIVE: To investigate the clinical significance of germline DNA-repair gene alterations in men with metastatic castration-resistant prostate cancer (mCRPC) receiving next-generation hormonal therapy (NHT), with a particular emphasis on BRCA/ATM mutations. DESIGN, SETTING, AND PARTICIPANTS: We interrogated 50 genes for pathogenic or likely pathogenic germline mutations using leukocyte DNA from 172 mCRPC patients beginning treatment with first-line NHT with abiraterone or enzalutamide...
February 10, 2018: European Urology
https://www.readbyqxmd.com/read/29438951/enhanced-reactivity-of-nzvi-embedded-into-supermacroporous-cryogels-for-highly-efficient-cr-vi-and-total-cr-removal-from-aqueous-solution
#2
Zhenzhen Jia, Yuehong Shu, Renlong Huang, Junguang Liu, Lingling Liu
Novel supermacroporous PSA-nZVI composites with nanoscale zero-valent iron particles (nZVI) embedded into poly (sodium acrylate) (PSA) cryogels were synthesized through ion exchange followed by in-situ reduction. The magnetic composites were evaluated for material characterizations and their efficiency for Cr(VI) and total Cr removal from aqueous medium in batch experiments. PSA-nZVI composites with high nZVI loading capacity up to 128.70 mg Fe/g PSA were obtained, and the interconnected macroporous structure of PSA cryogel remained unaltered with nZVI uniformly distributed on PSA cryogel as determined by TGA, SEM, TEM, XRD and XPS analyses...
February 7, 2018: Chemosphere
https://www.readbyqxmd.com/read/29433453/male-brca-mutation-carriers-clinical-characteristics-and-cancer-spectrum
#3
Mohammed Ibrahim, Siddhartha Yadav, Foluso Ogunleye, Dana Zakalik
BACKGROUND: Mutations in BRCA1 and BRCA2 (BRCA1/2) genes are associated with an increased risk of breast and ovarian cancers in women. The cancer characteristics of men with BRCA1/2 mutations are less well studied. This study describes the unique cancer characteristics of male BRCA1/2 mutation carriers at our institution. METHODS: We performed a retrospective chart review on male patients who were seen between January 2004 and December 2014 and tested positive for a BRCA1/2 mutation...
February 13, 2018: BMC Cancer
https://www.readbyqxmd.com/read/29432339/18f-choline-pet-mr-can-detect-and-delineate-local-recurrence-after-high-intensity-focused-ultrasound-therapy-of-prostate-cancer
#4
Irene A Burger, Andrei Gafita, Julian Müller, Benedikt Kranzbühler, Olivio F Donati, Daniel Eberli
Restaging local recurrence after high-intensity focused ultra-sound (HIFU) is based on multiparametric MRI (mpMRI). However, postinterventional changes of the tissue, such as edema or hemorrhage, are limiting tumor detection on mpMRI. We present a case of a rising prostate-specific antigen values, negative mpMRI, and a Gleason score of 4+4 on template biopsy after HIFU. On F-choline PET/MR, high focal uptake was detected at the location of positive biopsy. Re-HIFU based on the fused F-choline PET/MR images was performed, followed by a recurrence-free period of 11 months...
February 9, 2018: Clinical Nuclear Medicine
https://www.readbyqxmd.com/read/29431193/circulating-tumor-cells-and-survival-in-abiraterone-and-enzalutamide-treated-patients-with-castration-resistant-prostate-cancer
#5
Bram De Laere, Steffi Oeyen, Peter Van Oyen, Christophe Ghysel, Jozef Ampe, Piet Ost, Wim Demey, Lucien Hoekx, Dirk Schrijvers, Barbara Brouwers, Willem Lybaert, Els Everaert, Piet Van Kerckhove, Daan De Maeseneer, Michiel Strijbos, Alain Bols, Karen Fransis, Nick Beije, Inge de Kruijff, Valerie van Dam, Anja Brouwer, Pieter-Jan van Dam, Gert Van den Eynden, Annemie Rutten, Stefan Sleijfer, Jean Vandebroek, Steven Van Laere, Luc Dirix
BACKGROUND: The outcome to treatment administered to patients with metastatic castration-resistant prostate cancer (mCRPC) greatly differs between individuals, underlining the need for biomarkers guiding treatment decision making. OBJECTIVE: To investigate the prognostic value of circulating tumor cell (CTC) enumeration and dynamics, in the context of second-line endocrine therapies (ie, abiraterone acetate or enzalutamide), irrespective of prior systemic therapies...
February 12, 2018: Prostate
https://www.readbyqxmd.com/read/29429895/first-postoperative-psa-is-associated-with-outcomes-in-patients-with-node-positive-prostate-cancer-results-from-the-search-database
#6
Michelle L McDonald, Lauren E Howard, William J Aronson, Martha K Terris, Matthew R Cooperberg, Christopher L Amling, Stephen J Freedland, Christopher J Kane
OBJECTIVE: To analyze factors associated with metastases, prostate cancer-specific mortality, and all-cause mortality in pN1 patients. MATERIALS AND METHODS: We analyzed 3,642 radical prostatectomy patients within the Shared Equal Access Regional Cancer Hospital (SEARCH) database. Pathologic Gleason grade, number of lymph nodes (LN) removed, and first postoperative prostate-specific antigen (PSA) (<0.2 ng/ml or ≥0.2 ng/ml) were among covariates assessed. Cox regression was used to analyze the association between characteristics and survival outcomes...
February 8, 2018: Urologic Oncology
https://www.readbyqxmd.com/read/29420164/apalutamide-treatment-and-metastasis-free-survival-in-prostate-cancer
#7
Matthew R Smith, Fred Saad, Simon Chowdhury, Stéphane Oudard, Boris A Hadaschik, Julie N Graff, David Olmos, Paul N Mainwaring, Ji Youl Lee, Hiroji Uemura, Angela Lopez-Gitlitz, Géralyn C Trudel, Byron M Espina, Youyi Shu, Youn C Park, Wayne R Rackoff, Margaret K Yu, Eric J Small
Background Apalutamide, a competitive inhibitor of the androgen receptor, is under development for the treatment of prostate cancer. We evaluated the efficacy of apalutamide in men with nonmetastatic castration-resistant prostate cancer who were at high risk for the development of metastasis. Methods We conducted a double-blind, placebo-controlled, phase 3 trial involving men with nonmetastatic castration-resistant prostate cancer and a prostate-specific antigen doubling time of 10 months or less. Patients were randomly assigned, in a 2:1 ratio, to receive apalutamide (240 mg per day) or placebo...
February 8, 2018: New England Journal of Medicine
https://www.readbyqxmd.com/read/29398263/expression-of-androgen-receptor-splice-variant-7-or-9-in-whole-blood-does-not-predict-response-to-androgen-axis-targeting-agents-in-metastatic-castration-resistant-prostate-cancer
#8
Sarah Q To, Edmond M Kwan, Heidi C Fettke, Andrew Mant, Maria M Docanto, Luciano Martelotto, Patricia Bukczynska, Nicole Ng, Lisa-Jane K Graham, Phillip Parente, Carmel Pezaro, Kate Mahon, Lisa Horvath, Tilman Todenhöfer, Arun A Azad
In 2014, a landmark study was published demonstrating that the expression of androgen receptor splice variant (AR-V) 7 was a negative predictive biomarker for response to abiraterone acetate and enzalutamide in metastatic castration-resistant prostate cancer (mCRPC) patients. However, these results were not supported by the recently reported ARMOR3-SV phase III clinical trial, which employed an identical circulating tumour cell assay to assess AR-V7 expression. Therefore, the predictive utility of AR-V7 expression in mCRPC remains uncertain, as does any potential association between other AR-Vs and treatment response...
February 2, 2018: European Urology
https://www.readbyqxmd.com/read/29395502/docetaxel-versus-surveillance-after-radical-prostatectomy-for-high-risk-prostate-cancer-results-from-the-prospective-randomised-open-label-phase-3-scandinavian-prostate-cancer-group-12-trial
#9
Göran M Ahlgren, Per Flodgren, Teuvo L J Tammela, Pirkko Kellokumpu-Lehtinen, Michael Borre, Anders Angelsen, Jon Reidar Iversen, Asgerdur Sverrisdottir, Eirikur Jonsson, Lisa Sengelov
BACKGROUND: Adjuvant chemotherapy is standard treatment for other solid tumours, but to date has not proven effective in prostate cancer. OBJECTIVE: o evaluate whether six cycles of docetaxel alone improve biochemical disease-free survival after radical prostatectomy for high-risk prostate cancer. DESIGN, SETTING, AND PARTICIPANTS: Open-label, randomised multinational phase 3 trial. Enrolment of 459 patients after prostatectomy. INCLUSION CRITERIA: high-risk pT2 margin positive or pT3a Gleason score ≥4+3, pT3b, or lymph node positive disease Gleason score ≥3+4...
January 27, 2018: European Urology
https://www.readbyqxmd.com/read/29392121/incidental-prostate-cancer-a-10-year-review-of-a-tertiary-center-tehran-iran
#10
Amir-Reza Abedi, Morteza Fallah-Karkan, Farzad Allameh, Arash Ranjbar, Afshin Shadmehr
Objective: Incidental prostate cancer (IPCa) is defined as a symptom-free cancer unexpectedly discovered upon microscopic examination of resected tissue. The aim of this study was to report the correlation between some specific clinical criteria in patients incidentally diagnosed with prostate cancer (PCa) during transurethral resection of the prostate (TURP) or open prostatectomy (OP) after clinically suspected benign prostatic hyperplasia. Patients and methods: This was a cross-sectional, retrospective study...
2018: Research and Reports in Urology
https://www.readbyqxmd.com/read/29388324/taxane-chemotherapy-versus-anti-androgen-agents-as-first-line-therapy-for-metastatic-castration-resistant-prostate-cancer
#11
Guru Sonpavde, Ahong Huang, Li Wang, Onur Baser, Raymond Miao
OBJECTIVES: To assess treatment patterns and outcomes of patients with metastatic castration-resistant prostate cancer (mCRPC) receiving first-line chemotherapy or anti-androgen therapy. PATIENTS AND METHODS: Patients initiating first-line anti-androgen therapy (abiraterone, enzalutamide) or chemotherapy (taxane) from Oct/2012-Sept/2014 were retrospectively identified in the US Veterans Health Administration (VHA) database. The impact of anti-androgen therapy versus chemotherapy on overall survival (OS) and time to discontinuation was assessed using Cox proportional hazard models, adjusting for prior androgen deprivation therapy (ADT) duration and available prognostic factors...
February 1, 2018: BJU International
https://www.readbyqxmd.com/read/29386538/a-comparative-study-of-aptasensor-vs-immunosensor-for-label-free-psa-cancer-detection-on-gqds-aunrs-modified-screen-printed-electrodes
#12
Monika Srivastava, Narsingh R Nirala, S K Srivastava, Rajiv Prakash
Label-free and sensitive detection of PSA (Prostate Specific Antigen) is still a big challenge in the arena of prostate cancer diagnosis in males. We present a comparative study for label-free PSA aptasensor and PSA immunosensor for the PSA-specific monoclonal antibody, based on graphene quantum dots-gold nanorods (GQDs-AuNRs) modified screen-printed electrodes. GQDs-AuNRs composite has been synthesized and used as an electro-active material, which shows fast electron transfer and catalytic property. Aptamer or anti-PSA has immobilized onto the surface of modified screen printed electrodes...
January 31, 2018: Scientific Reports
https://www.readbyqxmd.com/read/29384928/prostate-cancer-treated-with-reduced-volume-intensity-modulated-radiation-therapy-report-on-the-5-year-outcome-of-a-prospective-series
#13
Hua-Chun Luo, Zhi-Chao Fu, Hui-Hua Cheng, Yong Lei, Shao-Guang Liao, Jing Feng, Qin Yin, Qun-Hua Chen, Gui-Shan Lin, Jin-Feng Zhu, Jian-Feng Xu, Wang Dian
How to define a clinical target volume (CTV) as small as possible for prostate cancer to reduce the dose received by normal organs is an interesting study. We conduct a research to analyze the clinical efficacy of intensity modulated radiotherapy (IMRT) using reduced CTV in the treatment of prostate cancer. From January 2006 to June 2010, 78 patients with prostate cancer were treated with IMRT according to this institutional protocol. Of them, 18 had stage II tumors, 39 had stage III tumors, and 21 had stage IVa tumors...
December 2017: Medicine (Baltimore)
https://www.readbyqxmd.com/read/29383406/use-of-androgen-deprivation-and-salvage-radiation-therapy-for-patients-with-prostate-cancer-and-biochemical-recurrence-after-prostatectomy
#14
Pirus Ghadjar, Daniel M Aebersold, Clemens Albrecht, Dirk Böhmer, Michael Flentje, Ute Ganswindt, Stefan Höcht, Tobias Hölscher, Felix Sedlmayer, Frederik Wenz, Daniel Zips, Thomas Wiegel
AIM: Overview on the use of androgen deprivation therapy (ADT) added to salvage radiation therapy (SRT) for prostate cancer patients with biochemical recurrence after prostatectomy. METHODS: The German Society of Radiation Oncology (DEGRO) expert panel summarized available evidence published between January 2009 and May 2017, and assessed the validity of the information on outcome parameters including overall survival (OS) and treatment-related toxicity. RESULTS: Two randomized controlled trials and nine relevant retrospective analyses were identified...
January 30, 2018: Strahlentherapie und Onkologie: Organ der Deutschen Röntgengesellschaft ... [et Al]
https://www.readbyqxmd.com/read/29383035/abiraterone-acetate-and-prednisone-in-the-pre-and-post-docetaxel-setting-for-metastatic-castration-resistant-prostate-cancer-a-mono-institutional-experience-focused-on-cardiovascular-events-and-their-impact-on-clinical-outcomes
#15
Alessia Cavo, Alessandra Rubagotti, Elisa Zanardi, Chiara Fabbroni, Linda Zinoli, Antonio Di Meglio, Eleonora Arboscello, Andrea Bellodi, Paolo Spallarossa, Carlo Cattrini, Carlo Messina, Francesco Boccardo
Background: The aim of this work was to to evaluate the incidence and risk factors of adverse events (AEs), focusing on cardiovascular events (CVEs) and hypokalemia, in patients treated with abiraterone acetate (AA) and prednisone (PDN) outside clinical trials, and their association with survival outcomes. Methods: This was a retrospective cohort study of 105 patients treated from 2011 to 2016. Incidence of AEs was descriptively summarized in the whole cohort and by subgroup (pre- versus post-docetaxel)...
2018: Therapeutic Advances in Medical Oncology
https://www.readbyqxmd.com/read/29379640/a-prospective-clinical-study-of-the-implications-of-il-8-in-the-diagnosis-aggressiveness-and-prognosis-of-prostate-cancer
#16
Thierry Roumeguère, Francois Legrand, Elie El Rassy, Mehdi Idrissi Kaitouni, Simone Albisinni, Alexandre Rousseau, Michel Vanhaeverbeek, Sandrine Rorive, Christine Decaestecker, Olivier Debeir, Karim Zouaoui Boudjeltia, Fouad Aoun
Aim: We evaluated the relationship between IL-8 and prostate cancer (PCa) with emphasis on diagnosis, aggressiveness and prognosis. Materials & methods: Prostate-specific antigen (PSA) and serum IL-8 were collected from patients undergoing prostate biopsy. IL-8 expression was evaluated on immunohistochemistry with IL-8 labeling index. Complete follow-up of this cohort was achieved over a period of up to 6 years with continuous follow-up of PSA levels. Results: Among 135 patients, serum IL-8 level did not correlate to the diagnosis or aggressiveness of PCa...
February 2018: Future Science OA
https://www.readbyqxmd.com/read/29377270/frontal-fibrosing-alopecia-after-antiandrogen-hormonal-therapy-in-a-male-patient
#17
LETTER
A Lobato-Berezo, A March-Rodríguez, G Deza, M Bertolín-Colilla, R M Pujol
No abstract text is available yet for this article.
January 29, 2018: Journal of the European Academy of Dermatology and Venereology: JEADV
https://www.readbyqxmd.com/read/29374406/minimum-residual-disease-in-patients-post-radical-prostatectomy-for-prostate-cancer-theoretical-considerations-clinical-implications-and-treatment-outcome
#18
Nigel P Murray, Socrates Aedo, Cynthia Fuentealba, Eduardo Reyes, Anibal Salazar
Introduction: Minimal residual disease (MRD) remaining after curative therapy for prostate cancer has the potential for growth and can result in metastasis. Circulating prostate cells (CPCs) and bone marrow micro-metastasis (mM) could represent different types of MRD. We here determined; biochemical failure free survival rates; time to BF after 10 years follow-up; and the presence of CPCs and mM in patients treated with radical prostatectomy (RP) for prostate cancer. Methods and Patients: One month after RP, blood and bone marrow were sampled for assessment of CPCs and mM...
January 27, 2018: Asian Pacific Journal of Cancer Prevention: APJCP
https://www.readbyqxmd.com/read/29370662/-availability-of-local-therapy-to-castration-resistant-prostate-cancer-for-m0-patients-with-initial-prostate-specific-antigen-100-ng-ml-or-higher
#19
Akito Kuromoto, Takaki Tanaka, Juntaro Koyama, Takuro Goto, Shingo Kimura, Yuki Katsumata, Shingo Myoen, Michinobu Ozawa, Kento Morozumi, Masahiko Sato, Senji Hoshi, Kenji Numahata, Yoichi Arai
Prostate cancer patients with initial PSA 100 ng/ml or greater who received transrectal ultrasoundguided prostate biopsy and were staged as M0 by imaging studies from 2011 to 2014 in seven hospitals, were enrolled in the study. Castration-resistant prostate cancer (CRPC)-free survival was compared between the two treatment groups : androgen deprivation therapy (ADT) alone and ADT plus local therapy. Of 142 prostate cancer patients with initial PSA 100 ng/ml or greater, 49 (34.5%) had no metastases and final analysis was performed on 46 patients...
December 2017: Hinyokika Kiyo. Acta Urologica Japonica
https://www.readbyqxmd.com/read/29366641/subcutaneous-fat-distribution-is-a-prognostic-biomarker-for-men-with-castration-resistant-prostate-cancer
#20
Jong Soo Lee, Hye Sun Lee, Jee Soo Ha, Kyung Suk Han, Koon Ho Rha, Sung Joon Hong, Byung Ha Chung, Kyo Chul Koo
PURPOSE: The relationship between body fat distribution and survival remains unclear among patients with castration-resistant prostate cancer (CRPC) treated using docetaxel and androgen receptor-axis targeted agents. We investigated whether body composition parameters could predict radiographic progression-free survival (RFS) and cancer-specific survival (CSS) among patients with CRPC. MATERIALS AND METHODS: This multi-center retrospective study evaluated data from 282 consecutive patients who were diagnosed with CRPC between September 2009 and March 2017...
January 20, 2018: Journal of Urology
keyword
keyword
25554
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"